Sep 11, 2017 11:01 am UTC| Business
Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces Hereditary Angioedema Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial ...
Sep 11, 2017 11:00 am UTC| Business
CAMBRIDGE, Mass. and OXFORD, United Kingdom, Sept. 11, 2017 -- Summit Therapeutics (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C....
Pilgrim’s Acquires Moy Park for $1.3 Billion (£1.0 Billion)
Sep 11, 2017 11:00 am UTC| Business
Creates Leading Global Poultry and Prepared Foods Company Increases Pilgrim’s Geographic Diversity by Expanding Operations Across the UK and Continental Europe Transaction Expected to be Immediately Accretive to...
Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017
Sep 11, 2017 11:00 am UTC| Business
NEW YORK, Sept. 11, 2017 -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced the presentation of clinical data...
Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market
Sep 11, 2017 11:00 am UTC| Business
SAN DIEGO, Sept. 11, 2017 -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has entered into definitive...
Operation Homefront Selects Dallas Veteran for Mortgage-Free Meritage Home
Sep 11, 2017 11:00 am UTC| Business
SCOTTSDALE, Ariz., Sept. 11, 2017 -- Operation Homefront and Meritage Homes Corporation (NYSE:MTH) today announced that a deserving military family has been selected to receive a newly built mortgage-free home in...
Sep 11, 2017 11:00 am UTC| Business
Confirmed Objective Response Rate (ORR) of 34%, Two Confirmed Complete Responses (CRs) and Twelve Confirmed Partial Responses (PRs) Median Duration of Response (DOR) of 12.6 Months Median Progression-Free Survival (PFS)...